Available Until 2/4/2025

Intensive Studies for Recertification: Pediatric Pharmacy (Cert # L249017)

ACPE Numbers: Various – see listing below
Content Release Date: 02/07/2024
Expiration Date: 02/04/2025
Activity Type: Application-based
CE Credits: 4 contact hours
Activity Fee: $105 (ASHP member); $160 (non-member)

Activity Overview

These activities were presented as part of the 2023 Midyear Clinical Meeting. Learners who claimed ACPE credit for these activities as part of that meeting should not claim ACPE credit again.

The Intensive Studies Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pediatric pharmacy. 

The Pediatric Pharmacy Intensive Studies Recertification Package consists of 3 activities (see table below) and provides up to 4.0 contact hours of continuing pharmacy education and/or recertification credit. 

These activities are part of the ASHP professional development program for BCPPS recertification approved by BPS. For pharmacists who maintain more than one certification, 2 of the activities are approved for multiple specialties (see table below).

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

  • Pediatric drug formulations
  • Procedural sedation
  • Drug allergy management

Board certified pharmacists are eligible to receive up to 4 contact hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. Learners will have a maximum of two opportunities to successfully complete each assessment. Recertification credit is earned in the calendar year in which you pass the recertification assessment.

ASHP is approved by BPS as a provider for the recertification of BCPPS.

Learning Activity

Passing Score

Credit Information

New Kids on the Block: The Future of Pediatric Drug Formulations 


1.0 Contact Hours

ACPE: 0204-0000-23-244-H01-P

Dream of the Endless: Updates in Procedural Sedation


1.5 Contact Hours

ACPE: 0204-0000-23-309-H01-P

Making the Grade: Approaches to Drug Allergy Management 


1.5 Contact Hours


ACPE: 0204-0000-23-239-H01-P

New Kids on the Block: The Future of Pediatric Drug Formulations
ACPE #: 0204-0000-23-244-H01-P

  • List common administration problems with currently available oral and intravenous dosage forms for children.
  • Describe newer solid oral dosage forms for children, including their advantages and the new challenges that they present.
  • Recommend the safe use of newer oral dosage forms when they become commercially available.
  • Choose an appropriate dosage form for a patient based on disease and patient-specific considerations.

This activity is approved for Board Certified Pediatric Pharmacy Specialist (BCPPS) recertification credit. 

Dream of the Endless: Updates in Procedural Sedation
ACPE #: 0204-0000-23-309-H01-P

  • Evaluate the most current literature regarding agents used for sedation and analgesia in the setting of procedural sedation.
  • Discuss patient-specific variables that have the potential to impact the safety and efficacy of the various pharmacotherapy options used in procedural sedation.
  • Critique procedural sedation pharmacotherapy implementation strategies with the goal of optimizing pharmacokinetic and pharmacodynamic principles.
  • Recognize options for alternative routes of administration and potential considerations based on patient-specific factors.
  • Identify important components that should be included in workflows and protocols for procedural sedation (e.g., stocking atomizers for intranasal administration, antidote availability, bedside monitoring).

This activity is approved for Board Certified Pediatric Pharmacy Specialist (BCPPS) and Board Certified Critical Care Pharmacist (BCCCP) recertification credit. 

Making the Grade: Approaches to Drug Allergy Management
ACPE #: 0204-0000-23-239-H01-P

  • Compare and contrast skin testing, graded challenges, and desensitization as approaches to drug allergy management.
  • Evaluate current literature on drug allergy management approaches and their impact on patient outcomes.
  • Design an appropriate care plan given the results of a patient's allergy assessment.

This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.

Faculty bios

Abby M. Bailey, PharmD, BCCCP
Coordinator, Emergency Medicine
University of Kentucky HealthCare
Lexington, Kentucky

Robbie L. Christian, PharmD, AAHIVP, BCIDP
Infectious Diseases Clinical Pharmacy Specialist / ID PGY2 Residency Program Director
VA Northeast Ohio Health Care
Cleveland, Ohio 

Yewande Dayo, PharmD, BCIDP
System Antimicrobial Stewardship Clinical Pharmacist
Ochsner Health
New Orleans, Louisiana

Rena A. Gosser, PharmD, BCPS, FASHP
Assistant Director, Specialty Pharmacy Services and Medication Access
University of Washington Medicine
Clinical Assistant Professor
University of Washington School of Pharmacy
Seattle, Washington 

Rachel S. Meyers, PharmD, BCPS, BCPPS
Clinical Associate Professor
Ernest Mario School of Pharmacy, Rutgers University
New Brunswick, NJ
Pediatric Clinical Pharmacist
Saint Barnabas Medical Center
Livingston, New Jersey

Kyle Weant, PharmD, BCPS, BCCCP, FCCP
Clinical Assistant Professor and Emergency Medicine Clinical Pharmacy Specialist
University of South Carolina College of Pharmacy
Columbia, South Carolina

Content Matter Experts

Peter N. Johnson, PharmD, BCPPS, BCPS, FCCM, FPPAG
Jamie L. Miller, PharmD, BCPPS, BCPS, FPPAG
Paul M. Szumita, PharmD, BCCCP, BCPS, FASHP, FCCM
Jennifer L. Thackray, PharmD, BCPPS, BCPS

Sue Dombrowski, MS, RPh

Hakeem Abayomi, PharmD, BS, BCPS, BCPPS, BCIDP, BCCCP
Uzma Ahmed, PharmD, BCCCP
Eugene Bush, BSPharm, PhD, Pharmacol, BCPS, BCCCP
Emily Chen, PharmD, BCPPS
Aaron Cooper, PharmD BCPPS
Adamma Davis, PharmD, BCPS, BCNSP
Emily Deremiah, PharmD, BCCCP
Andrea Dunlop, PharmD, BCPS
Ahmed Eid, PharmD, BCPS
Charisa Flaherty, PharmD, BCPPS
Jessica Frye, PharmD, BCPPS
Tatum Hamilton, PharmD, BCPPS
Yorika Hammett, PharmD, BCCCP
Aaron Harthan, PharmD, BCPPS
Laila Hasham, PharmD
Rebecca Hilton, PharmD, BCCCP
Allyson Howard, PharmD, BCPS
Miranda Howland, Pharm D, BCCCP
Jason Jones, BCPS, BCCCP
Bethany Jumps, PharmD, BCPS
Malia Kleespies, PharmD, BCPPS
Emily Kurzen, PharmD, BCPPS
Daisy Leong, PharmD, BCPS, BCSCP
Zarema Muratova, BSPharm, BCPPS
Brittany Parker, PharmD, BCPS, CPPS
Dipti Patel, PharmD, BCCCP, BCIDP, BCPS
Angela Paul, PharmD, BCPS
Amanda Penland, PharmD, BCPPS
Inna Perinskaya, PharmD, BCCCP
Tracy Peterson, PharmD, BCPS, BCCCP
Bambi Randall, PharmD, BCPS
Antonio Rivera, PharmD, BCPS, MBA
Gabriella Sarver, PharmD, BCPS, BCCCP
Kanan Shah, PharmD, MBA, BCPS, BCCCP, CPPS
Bridger Singer, PharmD, BCPS, BCCCP
Melissa Sterling, PharmD, BCCCP
Bovornpat Suriyapakorn, PharmD, BCPS, BCGP
Melvis Tabe, PharmD, BCPPS
Elizabeth Tesch, PharmD, BCPS, BCCP
Anh Vu, PharmD, BCPS, BCCCP
Stephanie Weightman, PharmD, BCPS, BCPPS, BCEMP
Corrie Weiland, PharmD, MBA, BCPS
Barbara Zarowitz, PharmD, BCPS, BCGP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity's content have relevant financial relationships:

  • Rachel Meyers – Consultant, CP Pharma; consultant, Wolters Kluwer

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations.  Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

These activities were developed by ASHP.